

Name of Sponsor/Company: Mutual Pharmaceutical Co., Inc. 1100 Orthodox Street Philadelphia, PA 19124	Page 2 of 2	Mutual Pharmaceutical Company, Inc <i>This report is the property of Mutual Pharmaceutical Company, Inc, and may not be used without the permission of Mutual Pharmaceutical Co., Inc.</i>
Name of Finished Product: Zonisamide Capsules, 100mg	Report Date: March 2005	
Name of Active Ingredient: Zonisamide	Final Report Number: R04-1377	

Criteria for evaluation: Bioequivalence

SUMMARY – CONCLUSIONS

Bioequivalence: Mutual Pharmaceutical’s Zonisamide Capsules, 100mg were bioequivalent to Elan Biopharmaceutical’s Zonegran® Capsules, 100mg with respect to C_{max}, AUC₀₋₇₂ when administered under fasting conditions. The results are summarized in the table below:

Zonisamide	Ln-Transformed C_{max}	Ln Transformed AUC₀₋₇₂
Test Product Geometric	887.97	39429.73
Reference Product Geometric Mean	898.54	39499.56
% Ratio	98.82	99.82
90% Confidence Interval	(96.17, 101.55)	(97.85, 101.83)